Dihydroartemisinin‑Piperaquine Tablets is a first‑line artemisinin‑based combination therapy (ACT) indicated for the treatment of acute uncomplicated malaria caused by Plasmodium falciparum, including cases with multidrug resistance.
The formulation combines two complementary antimalarials:
Dihydroartemisinin: A fast‑acting artemisinin derivative that rapidly eliminates early‑stage malaria parasites.
Piperaquine: A long‑acting blood schizonticide that provides sustained clearance and reduces the risk of recurrence.
This dual mechanism ensures rapid parasite clearance and helps minimize the development of antimalarial resistance.
Indications
For the treatment of acute uncomplicated malaria caused by Plasmodium falciparum in adults and children.
Key Features
Highly effective: Rapid reduction of parasite load with high cure rates.
Resistance management: Combines fast‑ and long‑acting agents to reduce resistance risk.
Convenient oral administration: Suitable for both adult and pediatric dosage forms.
Well‑tolerated: Favorable safety profile when used as directed.
Global compliance: Manufactured to meet international pharmacopoeial standards (USP, EP, BP).
Export‑ready: Complete registration dossiers and technical support available for global markets.
Storage
Store in a cool, dry place, protected from light and moisture. Keep out of reach of children.
Note
For prescription use only. Not recommended for malaria prophylaxis.
